Interim data show ixazomib improves progression free survival in relapsed and/or refractory myeloma patients

The Japanese pharmaceutical company, Takeda, has announced positive data from the first interim analysis of its pivotal trial investigating ixazomib as a potential treatment for relapsed and/or refractory myeloma. The results showed a significant improvement in progression free survival in patients receiving ixazomib in combination with Revlimid and dexamethasone compared to those receiving Revlimid and…

Details